Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company focused on drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its inclusion in both the Russell 2000® and Russell 3000® Indexes. The Russell 3000 Index represents the 3,000 largest U.S. companies by market cap, covering approximately 98% of the investable U.S. equity market, while the Russell 2000 Index focuses on the small-cap segment.
CEO Jeffrey Stein highlighted this milestone alongside other recent company achievements, including positive Phase 2b NAVIGATE trial results and a successful $400 million financing round. The index inclusion is expected to increase Cidara's visibility among institutional investors.
Cidara Therapeutics (Nasdaq: CDTX), un'azienda biotecnologica specializzata in terapie con coniugati farmaco-Fc attraverso la sua piattaforma Cloudbreak®, ha annunciato la sua inclusione negli indici Russell 2000® e Russell 3000®. L'indice Russell 3000 rappresenta le 3.000 maggiori società statunitensi per capitalizzazione di mercato, coprendo circa il 98% del mercato azionario investibile negli USA, mentre l'indice Russell 2000 si concentra sul segmento delle small cap.
Il CEO Jeffrey Stein ha sottolineato questo traguardo insieme ad altri recenti successi aziendali, tra cui i risultati positivi della fase 2b dello studio NAVIGATE e un round di finanziamento da 400 milioni di dollari andato a buon fine. L'inclusione negli indici dovrebbe aumentare la visibilità di Cidara tra gli investitori istituzionali.
Cidara Therapeutics (Nasdaq: CDTX), una empresa biotecnológica centrada en terapias con conjugados fármaco-Fc mediante su plataforma Cloudbreak®, ha anunciado su inclusión en los índices Russell 2000® y Russell 3000®. El índice Russell 3000 representa a las 3,000 mayores compañías estadounidenses por capitalización de mercado, abarcando aproximadamente el 98% del mercado de acciones invertible en EE. UU., mientras que el índice Russell 2000 se enfoca en el segmento de pequeñas capitalizaciones.
El CEO Jeffrey Stein destacó este hito junto con otros logros recientes de la compañía, incluyendo los resultados positivos del ensayo NAVIGATE en fase 2b y una exitosa ronda de financiamiento de 400 millones de dólares. Se espera que la inclusión en los índices aumente la visibilidad de Cidara entre los inversores institucionales.
Cidara Therapeutics (나스닥: CDTX)는 Cloudbreak® 플랫폼을 통한 약물-Fc 접합 치료제에 주력하는 생명공학 회사로, 러셀 2000® 및 러셀 3000® 지수에 모두 포함되었다고 발표했습니다. 러셀 3000 지수는 시가총액 기준 미국 내 상위 3,000개 기업을 대표하며, 미국 투자 가능한 주식 시장의 약 98%를 포괄하고, 러셀 2000 지수는 소형주 부문에 집중합니다.
CEO 제프리 스타인은 이 이정표와 함께 긍정적인 2b상 NAVIGATE 임상시험 결과 및 성공적인 4억 달러 자금 조달 등 최근 회사의 성과를 강조했습니다. 지수 포함은 기관 투자자들 사이에서 Cidara의 가시성을 높일 것으로 기대됩니다.
Cidara Therapeutics (Nasdaq : CDTX), une société biotechnologique spécialisée dans les thérapies par conjugués médicament-Fc via sa plateforme Cloudbreak®, a annoncé son inclusion aux indices Russell 2000® et Russell 3000®. L'indice Russell 3000 représente les 3 000 plus grandes entreprises américaines par capitalisation boursière, couvrant environ 98 % du marché boursier américain investissable, tandis que l'indice Russell 2000 se concentre sur le segment des petites capitalisations.
Le PDG Jeffrey Stein a souligné cette étape importante ainsi que d'autres réalisations récentes de l'entreprise, notamment les résultats positifs de l'essai de phase 2b NAVIGATE et une levée de fonds réussie de 400 millions de dollars. L'inclusion dans ces indices devrait accroître la visibilité de Cidara auprès des investisseurs institutionnels.
Cidara Therapeutics (Nasdaq: CDTX), ein Biotechnologieunternehmen, das sich auf Wirkstoff-Fc-Konjugat-Therapeutika über seine Cloudbreak®-Plattform spezialisiert hat, hat seine Aufnahme in die Russell 2000® und Russell 3000® Indizes bekanntgegeben. Der Russell 3000 Index umfasst die 3.000 größten US-Unternehmen nach Marktkapitalisierung und deckt etwa 98 % des investierbaren US-Aktienmarktes ab, während sich der Russell 2000 Index auf den Small-Cap-Sektor konzentriert.
CEO Jeffrey Stein hob diesen Meilenstein zusammen mit weiteren jüngsten Unternehmensleistungen hervor, darunter positive Ergebnisse der Phase-2b-NAVIGATE-Studie und eine erfolgreiche Finanzierungsrunde in Höhe von 400 Millionen US-Dollar. Die Aufnahme in die Indizes wird erwartet, die Sichtbarkeit von Cidara bei institutionellen Investoren zu erhöhen.
- Inclusion in both Russell 2000® and Russell 3000® Indexes, increasing institutional visibility
- Successfully completed $400 million financing round
- Reported positive data from Phase 2b NAVIGATE trial
- None.
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000® and Russell 3000® Indexes.
The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately
“Being included in the Russell 2000 and Russell 3000 Indexes is an important milestone for the company and represents the progress we continue to make,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Following the recent positive data from our Phase 2b NAVIGATE trial, as well as our successful
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of enrollment of its Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “intends,” “believes,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to the potential benefits of and future plans for CD388, a planned Phase 3 trial of CD388 and the expected timing for presenting additional results from the NAVIGATE trial. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s clinical trials and other risks related to clinical development, delays in action by regulatory authorities, other obstacles on the enrollment of patients or other aspects of CD388 or other DFC development and other risks and uncertainties associated with Cidara’s business in general. These and other risks are identified under the caption “Risk Factors” in Cidara’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and other filings subsequently made with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com
FAQ
What indexes was Cidara Therapeutics (CDTX) added to in June 2025?
What recent achievements did Cidara Therapeutics (CDTX) report along with the Russell indexes inclusion?
What is the significance of Cidara Therapeutics' inclusion in the Russell indexes?
What is Cidara Therapeutics' main technology platform?
